NeuroMetrix 관리

관리 기준 확인 2/4

NeuroMetrix CEO는 Shai Gozani, Jun1996 에 임명되었습니다 의 임기는 27.67 년입니다. 총 연간 보상은 $ 645.32K, 64.3% 로 구성됩니다. 64.3% 급여 및 35.7% 보너스(회사 주식 및 옵션 포함). 는 € 27.66K 가치에 해당하는 회사 주식의 0.81% 직접 소유합니다. 27.66K. 경영진과 이사회의 평균 재임 기간은 각각 10.5 년과 12.9 년입니다.

주요 정보

Shai Gozani

최고 경영자

US$645.3k

총 보상

CEO 급여 비율	64.3%
CEO 임기	27.7yrs
CEO 소유권	0.8%
경영진 평균 재임 기간	10.5yrs
이사회 평균 재임 기간	12.9yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Shai Gozani 의 보수는 NeuroMetrix 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2023	n/a	n/a	-US$6m
Jun 30 2023	n/a	n/a	-US$5m
Mar 31 2023	n/a	n/a	-US$5m
Dec 31 2022	US$645k	US$415k	-US$4m
Sep 30 2022	n/a	n/a	-US$5m
Jun 30 2022	n/a	n/a	-US$4m
Mar 31 2022	n/a	n/a	-US$3m
Dec 31 2021	US$558k	US$415k	-US$2m
Sep 30 2021	n/a	n/a	-US$2m
Jun 30 2021	n/a	n/a	-US$1m
Mar 31 2021	n/a	n/a	-US$1m
Dec 31 2020	US$181k	US$181k	-US$2m
Sep 30 2020	n/a	n/a	-US$3m
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	-US$6m
Dec 31 2019	US$775k	US$422k	-US$4m
Sep 30 2019	n/a	n/a	-US$6m
Jun 30 2019	n/a	n/a	-US$3m
Mar 31 2019	n/a	n/a	US$908k
Dec 31 2018	US$478k	US$415k	US$24k
Sep 30 2018	n/a	n/a	-US$54k
Jun 30 2018	n/a	n/a	-US$7m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	US$610k	US$415k	-US$20m

보상 대 시장: Shai 의 총 보상 ($USD 645.32K )은 German 시장( $USD 486.57K ).

보상과 수익: 회사가 수익성이 없는 동안 Shai 의 보상이 증가했습니다.

CEO

Shai Gozani (58 yo)

27.7yrs

테뉴어

US$645,324

보상

Dr. Shai N. Gozani, M.D., Ph D., founded Neurometrix Inc. in 1996 and has been its President since 2002 and Chief Executive Officer since 1997 and its Secretary July 2008. He has been the Chairman of the B...

리더십 팀

이름	위치	테뉴어	보상	소유권
Shai Gozani	Founder	27.7yrs	US$645.32k	0.81% € 27.7k
Thomas Higgins	Senior VP	14.4yrs	US$505.37k	0.63% € 21.5k
Xuan Kong	Chief Data Scientist	6.7yrs	데이터 없음	데이터 없음
Susan Bell	Senior Vice President of Population Health & Value Based Care	2.3yrs	데이터 없음	데이터 없음

10.5yrs

평균 재임 기간

경험이 풍부한 관리: NLZ0 의 관리팀은 노련하고 경험 (평균 재직 기간 10.5 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Shai Gozani	Founder	27.7yrs	US$645.32k	0.81% € 27.7k
Nancy Katz	Independent Director	13.2yrs	US$102.86k	0.21% € 7.0k
David Goodman	Independent Director	19.7yrs	US$107.86k	0.21% € 7.0k
Arthur Vinik	Member of Scientific Advisory Board	12.9yrs	데이터 없음	데이터 없음
Andrew Boulton	Member of the Scientific Advisory Board	12.9yrs	데이터 없음	데이터 없음
David Van Avermaete	Independent Director	10.4yrs	US$102.86k	0.21% € 7.0k
Neil Brooks	Member of the Scientific Advisory Board	12.9yrs	데이터 없음	데이터 없음
David Armstrong	Member of the Scientific Advisory Board	12.9yrs	데이터 없음	데이터 없음
Solomon Tesfaye	Member of the Scientific Advisory Board	12.9yrs	데이터 없음	데이터 없음
Dan Ziegler	Member of the Scientific Advisory Board	12.9yrs	데이터 없음	데이터 없음
Bruce Perkins	Member of the Scientific Advisory Board	12.9yrs	데이터 없음	데이터 없음
Jiro Nakamura	Member of Scientific Advisory Board	10.1yrs	데이터 없음	데이터 없음

12.9yrs

평균 재임 기간

65.5yo

평균 연령

경험이 풍부한 이사회: NLZ0 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 12.9 년).

NeuroMetrix 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Neurometrix, Inc. Appoints Joshua S. Horowitz as a Class III director on the Board

NeuroMetrix, Inc., Annual General Meeting, Apr 30, 2024

Insufficient new directors

Neurometrix, Inc. Appoints Jonathan Breck Harmel as National Director of Sales

NeuroMetrix, Inc. Appoints Brad Fluegel to Its Board of Directors, Effective July 1, 2022

Insufficient new directors

Recent updates

NeuroMetrix, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Neurometrix, Inc. Appoints Joshua S. Horowitz as a Class III director on the Board

NeuroMetrix, Inc., Annual General Meeting, Apr 30, 2024

NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

RS Fund Discloses its Views on NeuroMetrix

NeuroMetrix, Inc. to Report Q4, 2023 Results on Feb 22, 2024

NeuroMetrix, Inc. Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy

Third quarter 2023 earnings released: US$0.21 loss per share (vs US$0.23 loss in 3Q 2022)

NeuroMetrix, Inc. to Report Q3, 2023 Results on Oct 26, 2023

NeuroMetrix Receives Non-Compliance Notice From Nasdaq

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.20 loss per share (vs US$0.17 loss in 2Q 2022)

NeuroMetrix, Inc. to Report Q2, 2023 Results on Jul 27, 2023

NeuroMetrix, Inc. Announces Sales Force Expansion for Quell Fibromyalgia

NeuroMetrix, Inc. Announces Presentation of New Clinical Data At the Diabetes UK Meeting

NeuroMetrix, Inc. Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy

First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.14 loss in 1Q 2022)

Full year 2022 earnings released: US$0.62 loss per share (vs US$0.45 loss in FY 2021)

NeuroMetrix, Inc. to Report Q4, 2022 Results on Feb 23, 2023

NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

Insufficient new directors

NeuroMetrix, Inc. to Introduce Quell Fibromyalgia At the American College of Rheumatology 2022 Annual Meeting

NeuroMetrix, Inc. Announces Strategic Launch of Quell Fibromyalgia

Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.12 loss in 3Q 2021)

NeuroMetrix, Inc. to Report Q3, 2022 Results on Oct 20, 2022

Neurometrix, Inc. Appoints Jonathan Breck Harmel as National Director of Sales

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.13 loss in 2Q 2021)

NeuroMetrix, Inc. to Report Q2, 2022 Results on Jul 21, 2022

NeuroMetrix, Inc. Appoints Brad Fluegel to Its Board of Directors, Effective July 1, 2022

NeuroMetrix, Inc. Reports Quell(R) Wearable Neuromodulation Device Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

First quarter 2022 earnings released: US$0.14 loss per share (vs US$0.016 loss in 1Q 2021)

Insufficient new directors

NeuroMetrix, Inc. to Report Q1, 2022 Results on Apr 26, 2022

NeuroMetrix, Inc. Reports That Quell® Wearable Neuromodulator to Be Evaluated in Post-Acute Covid-19 Syndrome

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.068 loss in 3Q 2020)

Senior VP recently sold €449k worth of stock

Senior VP recently sold €231k worth of stock

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.28 loss in 2Q 2020)

NeuroMetrix, Inc. Announces Quell Technology

NeuroMetrix Announces Top-Line Results from a Randomized Controlled Trial of Quell for Treatment of Fibromyalgia to be Presented at Two Upcoming Pain Medicine Conferences

First quarter 2021 earnings released: US$0.016 loss per share (vs US$0.45 loss in 1Q 2020)

NeuroMetrix, Inc., Annual General Meeting, Apr 27, 2021

New 90-day high: €4.12

Full year 2020 earnings released: US$0.55 loss per share (vs US$3.90 loss in FY 2019)

NeuroMetrix, Inc. to Report Q4, 2020 Results on Jan 28, 2021

New 90-day high: €3.18

New 90-day high: €2.96

New 90-day high: €1.63

New 90-day low: €1.23

Third quarter earnings released

NeuroMetrix, Inc. to Report Q3, 2020 Results on Oct 22, 2020

NeuroMetrix, Inc. Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-The-Counter Pain Relief Device

New 90-day low - €1.47

NeuroMetrix, Inc. to Report Q2, 2020 Results on Jul 23, 2020

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령